大庆华科(000985) - 2018 Q1 - 季度财报

Revenue and Profitability - The company's revenue for Q1 2018 was ¥460,206,601.68, representing a 35.84% increase compared to ¥338,781,332.81 in the same period last year[6] - The net profit attributable to shareholders was a loss of ¥7,427,626.07, a decrease of 143.52% from a profit of ¥17,066,647.05 in the previous year[6] - The estimated cumulative net profit for the first half of 2018 is projected to be 5 million yuan, representing a decrease of 69.20% compared to the same period last year, which was 16.24 million yuan[18] - The basic earnings per share for the same period are expected to be 0.039 yuan, down 68.80% from 0.125 yuan in the previous year[18] - The total comprehensive income for Q1 2018 was -7,427,626.07 CNY, compared to 17,066,647.05 CNY in Q1 2017, reflecting a substantial decrease[27] Cash Flow and Operating Activities - The net cash flow from operating activities decreased by 68.23%, amounting to ¥6,433,976.19 compared to ¥20,251,532.66 in the previous year[6] - Cash flow from operating activities generated a net cash inflow of 6,433,976.19 CNY, a decrease from 20,251,532.66 CNY in the previous year[30] - Total cash inflow from operating activities was 539,935,157.73 CNY, compared to 394,154,102.51 CNY in the same period last year, indicating a year-over-year increase[30] - Cash outflow for purchasing goods and services was 491,667,898.89 CNY, up from 336,633,444.45 CNY in Q1 2017[30] - The net cash flow from investing activities was -10,857,016.02 CNY, compared to -4,463,752.24 CNY in the previous year, indicating increased investment outflows[31] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥701,410,017.34, a slight increase of 0.12% from ¥700,552,377.24 at the end of the previous year[6] - The total assets at the end of the reporting period are 701.41 million yuan, slightly up from 700.55 million yuan at the beginning of the period[25] - The total liabilities at the end of the reporting period are 153.87 million yuan, compared to 146.88 million yuan at the beginning of the period[24] - The company's cash and cash equivalents at the end of the reporting period are 221.86 million yuan, down from 226.28 million yuan at the beginning of the period[22] - The cash and cash equivalents at the end of the period totaled 221,859,302.75 CNY, down from 226,282,342.58 CNY at the beginning of the period[31] Operating Costs and Expenses - The cost of goods sold increased by 50.47%, amounting to ¥439,403,303.99 compared to ¥292,029,928.39 in the previous year[14] - The company reported a significant increase in sales expenses by 87.44%, reaching ¥3,620,563.99 compared to ¥1,931,544.55 in the previous year[14] - The total operating costs for the current period amount to 468.12 million yuan, up from 319.05 million yuan in the previous period[26] - The operating cost specifically for the current period is 439.40 million yuan, compared to 292.03 million yuan in the previous period[26] Future Outlook and Strategic Plans - The company anticipates a significant decline in operating performance for the first half of 2018 due to losses in the first quarter and potential fluctuations in oil prices[18] - The company attempted to sell assets from its pharmaceutical division but received no interested buyers during the reporting period[16] - The company plans to adjust the asset transfer price to attract potential buyers, reducing it to ¥5,661.95 million from the original valuation[16] - The company is nearing completion of its polypropylene capacity expansion project, which is expected to increase production and sales of polypropylene products[18]